Advancing Immunomodulatory Functions in Mesenchymal Stem/stromal Cells Through Targeting the GATA6-mediated Pathway

Overview

Journal Cytotherapy

Publisher Elsevier

Specialties Cell Biology
Pharmacology

Date 2024 Aug 29

PMID 39207345

Authors

Eric Chang-Yi Lin

Madison P Davis

Ming-Song Lee

Gui Ma

Wei Xu

Yuan-I Chang

Wan-Ju Li

Affiliations

Soon will be listed here.

Abstract

Background Aims: The immunomodulatory capacity of mesenchymal stem/stromal cells (MSCs) is a key feature that makes them particularly valuable for regenerative medicine. However, this potential is affected by the chronological aging of the donors and the cell expansion procedures in culture. We have demonstrated that GATA binding protein 6 (GATA6) plays a pivotal role in the aging of MSCs and inhibiting GATA6 rejuvenates the characteristics of MSCs.

Methods: In this study, we compared the immunomodulatory capabilities of young and old MSC models, using induced pluripotent stem cells-derived rejuvenated MSCs (rMSCs) and their parental MSCs (pMSCs), respectively, to identify a key mechanism involved in the differential regulation of these capabilities. Additionally, we explored the role of GATA6 in mediating the mechanism.

Results: Our results demonstrated that rMSCs exhibited downregulated aging-associated regulators, including p53, p21 and GATA6, and showed enhanced suppression of T cell proliferation compared to pMSCs. Through analyzing our previous RNA-seq data and employing target gene knockdown, we determined both suppressors of cytokine signaling 3 (SOCS3) and interleukin 6 were involved in GATA6-induced regulation, collectively affecting the expression of programmed death ligand 1 (PDL1) in both pMSCs and rMSCs.

Conclusions: Our findings underline the significance of the GATA6/SOCS3/PDL1 pathway in regulating aging-associated changes in MSC immunomodulatory activity, providing valuable insights into the potential use of rMSCs in the treatment of immune diseases and regenerative medicine.

References

Wang G, Zhang S, Wang F, Li G, Zhang L, Luan X . Expression and biological function of programmed death ligands in human placenta mesenchymal stem cells. Cell Biol Int. 2013; 37(2):137-48. DOI: 10.1002/cbin.10024. View

Onorati A, Havas A, Lin B, Rajagopal J, Sen P, Adams P . Upregulation of PD-L1 in Senescence and Aging. Mol Cell Biol. 2022; 42(10):e0017122. PMC: 9583718. DOI: 10.1128/mcb.00171-22. View

Wang W, Yen M, Liu K, Hsu P, Lin M, Chen P . Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. Stem Cell Reports. 2015; 5(3):392-404. PMC: 4618596. DOI: 10.1016/j.stemcr.2015.07.013. View

van den Akker F, Vrijsen K, Deddens J, Buikema J, Mokry M, van Laake L . Suppression of T cells by mesenchymal and cardiac progenitor cells is partly mediated via extracellular vesicles. Heliyon. 2018; 4(6):e00642. PMC: 6040605. DOI: 10.1016/j.heliyon.2018.e00642. View

Kim Y, Sung D, Bang Y, Sung S, Yang M, Ahn S . SOCS3 Protein Mediates the Therapeutic Efficacy of Mesenchymal Stem Cells against Acute Lung Injury. Int J Mol Sci. 2023; 24(9). PMC: 10179427. DOI: 10.3390/ijms24098256. View

Li M, Sun X, Kuang X, Liao Y, Li H, Luo D . Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-β. Clin Exp Immunol. 2014; 178(3):516-24. PMC: 4238878. DOI: 10.1111/cei.12423. View

Jiao H, Walczak B, Lee M, Lemieux M, Li W . GATA6 regulates aging of human mesenchymal stem/stromal cells. Stem Cells. 2020; 39(1):62-77. PMC: 7772271. DOI: 10.1002/stem.3297. View

Kizilay Mancini O, Lora M, Shum-Tim D, Nadeau S, Rodier F, Colmegna I . A Proinflammatory Secretome Mediates the Impaired Immunopotency of Human Mesenchymal Stromal Cells in Elderly Patients with Atherosclerosis. Stem Cells Transl Med. 2017; 6(4):1132-1140. PMC: 5442842. DOI: 10.1002/sctm.16-0221. View

Babon J, Varghese L, Nicola N . Inhibition of IL-6 family cytokines by SOCS3. Semin Immunol. 2014; 26(1):13-9. PMC: 3970923. DOI: 10.1016/j.smim.2013.12.004. View

10.

Wagner D, Karnik S, Gunderson Z, Nielsen J, Fennimore A, Promer H . Dysfunctional stem and progenitor cells impair fracture healing with age. World J Stem Cells. 2019; 11(6):281-296. PMC: 6600851. DOI: 10.4252/wjsc.v11.i6.281. View

11.

Spitzhorn L, Megges M, Wruck W, Rahman M, Otte J, Degistirici O . Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature. Stem Cell Res Ther. 2019; 10(1):100. PMC: 6423778. DOI: 10.1186/s13287-019-1209-x. View

12.

Moerman E, Teng K, Lipschitz D, Lecka-Czernik B . Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004; 3(6):379-89. PMC: 1850101. DOI: 10.1111/j.1474-9728.2004.00127.x. View

13.

Gao Y, Chi Y, Chen Y, Wang W, Li H, Zheng W . Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1. Nat Commun. 2023; 14(1):4373. PMC: 10359415. DOI: 10.1038/s41467-023-39958-5. View

14.

Liu Y, Chen Q . Senescent Mesenchymal Stem Cells: Disease Mechanism and Treatment Strategy. Curr Mol Biol Rep. 2021; 6(4):173-182. PMC: 8011589. DOI: 10.1007/s40610-020-00141-0. View

15.

Myneni V, McClain-Caldwell I, Martin D, Vitale-Cross L, Marko K, Firriolo J . Mesenchymal stromal cells from infants with simple polydactyly modulate immune responses more efficiently than adult mesenchymal stromal cells. Cytotherapy. 2019; 21(2):148-161. PMC: 6435420. DOI: 10.1016/j.jcyt.2018.11.008. View

16.

Bachus H, Mclaughlin E, Lewis C, Papillion A, Benveniste E, Hill D . IL-6 prevents Th2 cell polarization by promoting SOCS3-dependent suppression of IL-2 signaling. Cell Mol Immunol. 2023; 20(6):651-665. PMC: 10229632. DOI: 10.1038/s41423-023-01012-1. View

17.

Song N, Scholtemeijer M, Shah K . Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharmacol Sci. 2020; 41(9):653-664. PMC: 7751844. DOI: 10.1016/j.tips.2020.06.009. View

18.

Chinnadurai R, Rajan D, Ng S, McCullough K, Arafat D, Waller E . Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming. Blood Adv. 2017; 1(11):628-643. PMC: 5507374. DOI: 10.1182/bloodadvances.2017006205. View

19.

Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu B, Tato C . Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A. 2006; 103(21):8137-42. PMC: 1459629. DOI: 10.1073/pnas.0600666103. View

20.

Studer L, Vera E, Cornacchia D . Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency. Cell Stem Cell. 2015; 16(6):591-600. PMC: 4508309. DOI: 10.1016/j.stem.2015.05.004. View